VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Overview Fund Activity
Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

45 hedge funds and large institutions have $26.6M invested in Viracta Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 6 closing their positions.

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
0.98%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
7
Increased
14
Reduced
8
Closed
6
Calls
$101K
Puts
$5K
Net Calls
+$96K
Net Calls Change
+$76K

Top Buyers

1
BI
1
BVF Inc
California
$4.92M
2
NCM
2
Nantahala Capital Management
Connecticut
$3.24M
3
CC
3
Caxton Corporation
New Jersey
$1.92M
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.66M
5
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.02M

Top Sellers

1
EAM
1
Eventide Asset Management
Massachusetts
$0
2
SB
2
Samsara BioCapital
California
$1.53M
3
FI
3
Fosun International
China
$0
4
Balyasny Asset Management
4
Balyasny Asset Management
Illinois
$1.21M
5
Citadel Advisors
5
Citadel Advisors
Florida
$21K
Name Market Value Shares Shares
Change 		Shares
Change %
S
51
SignatureFD
Georgia
$0 2 – –
CFGS
52
Concourse Financial Group Securities
Alabama
– – – –
PA
53
Parallel Advisors
California
$0 1 – –
AG
54
Advisor Group
Arizona
$0 5 +5 New
1 2
3